Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Harald Hjelde"'
Autor:
Stein Kaasa, Sveinung Sørhaug, Harald Hjelde, Tora Skeidsvoll Solheim, Are Korsnes Kristensen, Tore Amundsen, Bjørn Henning Grønberg
Publikováno v:
Acta Oncologica
Background: Side effects of chemotherapy may occur at different time-points in the treatment cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. The current study examined the variation of HRQoL during chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761aa59e02de74075cf807726732061e
http://hdl.handle.net/11250/2450979
http://hdl.handle.net/11250/2450979
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer
Autor:
Tore Amundsen, Sveinung Sørhaug, Jorunn L. Helbostad, Harald Hjelde, Stein Kaasa, Guro Birgitte Stene, Bjørn Henning Grønberg
Publikováno v:
Acta Oncologica. 54:340-348
Sarcopenia is a defining feature of cancer cachexia associated with physical decline, poor quality of life and poor prognosis. Thus, maintaining muscle mass is an important aim of cachexia treatment. Many patients at risk for developing cachexia or w
Autor:
Marit S. Jordhøy, Bjørn Henning Grønberg, Øystein Fløtten, Harald Hjelde, Roy M. Bremnes, Stein Kaasa, Tore Amundsen, Christian von Plessen, Stein Sundstrøm
Publikováno v:
European Journal of Cancer. 46:2225-2234
To investigate whether patients with severe comorbidity receiving platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) have a shorter overall survival, experience more toxicity or more deterioration of health-related quality of
Autor:
Rune Haaverstad, Anne Britt Abusland, Harald Hjelde, Asbjørn Ødegård, Staal Hatlinghus, Stein Sundstrøm
Publikováno v:
Tidsskrift for Den norske legeforening. 130:25-28
BACKGROUND 2500 new cases of lung cancer are diagnosed in Norway annually. Patients with limited disease can be operated, but many will die from the disease despite surgical treatment. The aim of the study was to review survival and recurrence, and f
Autor:
O K Garpestad, Ulf Aasebø, A Bailey, P Fr Brunsvig, Nina Helbekkmo, C. Von Plessen, Roy M. Bremnes, Stein Sundstrøm, Harald Hjelde
Publikováno v:
British Journal of Cancer
This randomised phase III study in advanced non-small cell lung cancer (NSCLC) patients was conducted to compare vinorelbine/carboplatin (VC) and gemcitabine/carboplatin (GC) regarding efficacy, health-related quality of life (HRQOL) and toxicity. Ch
Autor:
Peter Hatlen, Majid Salarinejad, Tore Amundsen, Kristin Nesgård, Håkon Olav Leira, Raymond Hollund, Harald Hjelde, Dag Nordhaug, Bjarte Nesvik, Sveinung Sørhaug
Publikováno v:
1.4 Interventional Pulmonology.
Introduction: Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) has become an important diagnostic tool for the pulmonologist. At our institution, five bronchoscopists have performed EBUS-TBNA during the first 6 years of expe
Autor:
Sveinung, Sørhaug, Harald, Hjelde, Peter, Hatlen, Håkon Olav, Leira, Majid, Salarinejad, Bjarte, Nesvik, Raymond, Hollund, Kristin, Nesgård, Dag Ole, Nordhaug, Tore, Amundsen
Publikováno v:
The clinical respiratory journal. 12(1)
Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) has become an important diagnostic tool for the pulmonologist. Learning this procedure and maintaining technical skills requires continuous practice and evaluation.The aims of
Autor:
Peter Hatlen, Harald Hjelde, Ruby Mahesparan, Müller Tomm B, Sveinung Sørhaug, Håkon Olav Leira, Tore Amundsen
Publikováno v:
Journal of Pulmonary & Respiratory Medicine.
Introduction: In selected patients superior survival has been observed when treated aggressively for lung cancer and brain metastasis (BM). The aim of the study was to evaluate treatment-modalities and survival in our region retrospective. Method: Re
Autor:
Harald, Hjelde, Stein, Sundstrøm, Asbjørn, Ødegård, Staal, Hatlinghus, Anne Britt, Abusland, Rune, Haaverstad
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 130(1)
2500 new cases of lung cancer are diagnosed in Norway annually. Patients with limited disease can be operated, but many will die from the disease despite surgical treatment. The aim of the study was to review survival and recurrence, and factors whic
Autor:
Frøydis Stornes, Roy M. Bremnes, Øystein Fløtten, Finn Wammer, Stein Sundstrøm, P. Brunsvig, Harald Hjelde, Bjørn Henning Grønberg, Ulf Aasebø, Terje Tollåli
Publikováno v:
Journal of Thoracic Oncology. 2(8)